Civica Rx says it isn't afraid of competition

Civica Rx CEO Martin VanTrieste isn't afraid of competition, he says. In fact, he welcomes organizations that want to disrupt the system and reduce drug shortages affecting patient care, according to S&P Global.

Some companies are already adopting their own disruptive models, including Premier Inc., which recently launched Provide Gx, Mr. Van Trieste told S&P Global. 

He also cited a "remarkably similar" proposal by Sen. Elizabeth Warren, D-Mass., that would give the U.S. government power to make generic medications. 

Civica Rx was formed in September 2018 by a coalition of hospitals that sought to create a company to reduce the generic drug shortage in the U.S.

The nonprofit company expects to have its first product, the antibiotic vancomycin, available for hospitals by the end of this month.

"In my entire career, I've never seen anything take shape and have that much momentum and deliver so many results in such a fast period of time," Mr. VanTrieste told S&P Global.

Civica Rx expects to bring 16 products to market this year, according to the report.  Mr. VanTrieste said there are more than 200 drugs on the FDA's shortage list.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars

>